Critical Comparison: Nanovibronix (FEED) vs. Its Competitors

Nanovibronix (NASDAQ:FEED) is one of 29 public companies in the “Surgical, Medical, And Dental Instruments And Supplies” industry, but how does it contrast to its peers? We will compare Nanovibronix to related businesses based on the strength of its earnings, analyst recommendations, dividends, profitability, institutional ownership, valuation and risk.

Valuation and Earnings

This table compares Nanovibronix and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Nanovibronix	$2.56 million	-$3.70 million	-0.06
Nanovibronix Competitors	$60.44 million	-$32.15 million	4.20

Nanovibronix’s peers have higher revenue, but lower earnings than Nanovibronix. Nanovibronix is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of current recommendations and price targets for Nanovibronix and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanovibronix	1	0	0	0	1.00
Nanovibronix Competitors	77	77	156	6	2.29

As a group, “Surgical, Medical, And Dental Instruments And Supplies” companies have a potential upside of 47.87%. Given Nanovibronix’s peers stronger consensus rating and higher probable upside, analysts plainly believe Nanovibronix has less favorable growth aspects than its peers.

Institutional & Insider Ownership

16.4% of Nanovibronix shares are owned by institutional investors. Comparatively, 22.5% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are owned by institutional investors. 5.2% of Nanovibronix shares are owned by insiders. Comparatively, 18.4% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Nanovibronix and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nanovibronix	-275.12%	-24.78%	-19.24%
Nanovibronix Competitors	-672.41%	-133.75%	-59.01%

Volatility and Risk

Nanovibronix has a beta of 2.21, suggesting that its stock price is 121% more volatile than the S&P 500. Comparatively, Nanovibronix’s peers have a beta of 1.76, suggesting that their average stock price is 76% more volatile than the S&P 500.

Summary

Nanovibronix peers beat Nanovibronix on 8 of the 13 factors compared.

Nanovibronix Company Profile

NanoVibronix Inc. is a medical device company that is focused on creating medical products utilizing its proprietary low-intensity, surface acoustic wave technology. … NanoVibronix’ catheter-based products include the UroShield™ and NG-Shield™ devices that are both CE mark certified.